Omnicell
Automates medication dispensing, pharmacy compounding, and outpatient medication workflows.
Something off on this page? Send us feedback.
Profile
Sells automated dispensing cabinets, central-pharmacy and IV-compounding robotics, cloud software, consumables, and expert services across hospital and outpatient pharmacy settings. Revenue combines equipment and license sales with recurring technical support, subscriptions, and consumables, while remaining concentrated in the United States.
Builds medication-management infrastructure for hospitals, health systems, and pharmacies. Point-of-care dispensing cabinets, central-pharmacy robotics, IV-compounding automation, and the OmniSphere cloud platform connect medication storage, preparation, distribution, inventory, and diversion monitoring.
Extends beyond inpatient workflows through Specialty Pharmacy Services and 340B administration, the EnlivenHealth retail-pharmacy platform, and medication-adherence packaging and automation. Pairs connected hardware with cloud analytics and onsite or remote specialists, while earning recurring revenue from consumables, technical support, SaaS, and expert services.
Most revenue comes from the United States. Results depend on healthcare providers' capital and operating budgets, lengthy purchasing and installation cycles, reliable hardware and cloud software, access to specialty-drug networks, limited-source components, and evolving pharmacy, medical-device, privacy, and 340B rules.
Company facts
Key statistics
Year to date −26.7% · Average volume (30d) 795.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Keybanc | Reiterate | Overweight | $70 | $65 | |
| Jul 31, 2026 | Wells Fargo | Reiterate | Overweight | $52 | $50 | |
| Apr 29, 2026 | Craig-Hallum | Target | $55 | |||
| Apr 28, 2026 | KeyBanc | Target | $60 | $70 | ||
| Mar 13, 2026 | UBS | Target | $53 | $60 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.47 | $0.94 | +101.1% | $310.2M | $312.2M | +0.6% | −10.36% |
| Apr 28, 2026Q1 FY26 | $0.33 | $0.55 | +66.7% | $304.0M | $309.9M | +1.9% | −5.30% |
| Feb 5, 2026Q4 FY25 | $0.47 | $0.40 | −14.9% | $313.4M | $314.0M | +0.2% | −5.14% |
| Oct 30, 2025Q3 FY25 | $0.36 | $0.51 | +41.7% | $313.4M | $310.6M | −0.9% | −0.03% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $269.7M | $290.6M | $310.6M | $314.0M | $309.9M | $312.2M | |
| Gross profit | $110.9M | $127.7M | $134.5M | $130.3M | $140.4M | $152.9M | |
| Operating income | −$11.6M | $8.1M | $8.2M | $1.4M | $16.9M | $32.4M | |
| Net income | −$7.0M | $5.6M | $5.5M | −$2.0M | $11.4M | $24.3M | |
| Diluted EPS | −$0.15 | $0.12 | $0.12 | −$0.05 | $0.25 | $0.52 | |
| Gross margin | 41.1% | 43.9% | 43.3% | 41.5% | 45.3% | 49.0% | |
| Operating margin | -4.3% | 2.8% | 2.7% | 0.5% | 5.4% | 10.4% |
Fiscal years (4-quarter sums)FY21 $1.13B · FY22 $1.30B · FY23 $1.15B · FY24 $1.11B · FY25 $1.18B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $307.0M · Total debt $200.0M · Total assets $2.00B · Shareholders' equity $1.29B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 45.48M · Float 43.91M · 96.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.54M | 16.58% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 3.15M | 6.93% | 13F | Aug 13, 2026 |
| Wellington Management Group LLP | 2.70M | 5.94% | 13F | Aug 14, 2026 |
| Dimensional Fund Advisors LP | 2.45M | 5.39% | 13F | Aug 11, 2026 |
| State Street Corp | 2.09M | 4.59% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Nnamdi Njoku | officer: President & COO | −3,083 | $36.85 |
| Jul 15, 2026 | Randall A. Lipps | director, officer: CHAIRMAN, CEO | −10,000 | $47.00 |
| May 18, 2026 | Corey J. Manley | officer: EVP&CHIEF LEGAL/ADMIN OFFICER | −5,025 | $43.22 |
| May 18, 2026 | Nnamdi Njoku | officer: EVP, Chief Operating Officer | −3,090 | $43.22 |
| Mar 16, 2026 | Corey J. Manley | officer: EVP&CHIEF LEGAL/ADMIN OFFICER | −7,405 | $34.69 |
Peers
- BD
Direct Pyxis rival in hospital and pharmacy automation
- McKesson
Pharmacy services, 340B, and workflow adjacency
- Baxter International
IV workflow and pharmacy-preparation competitor
- Cencora
Specialty pharmacy and 340B services competitor
- Cardinal Health
Pharmacy distribution and specialty-services competitor
- ICU Medical
IV compounding automation rival around hazardous drugs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Omnicell | $33.08 | −0.03% | $1.50B | 39.2 | 18.4 | 1.2 | +7.5% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| McKesson | $887.21 | −0.76% | $104.60B | 23.9 | 19.3 | 0.3 | +7.7% |
| Baxter International | $26.30 | +0.65% | $13.51B | — | 12.5 | 1.2 | +5.3% |
| Cencora | $320.00 | −0.60% | $62.65B | 23.9 | 16.6 | 0.2 | +5.1% |
| Cardinal Health | $232.64 | −0.84% | $54.93B | 32.4 | 18.7 | 0.2 | +5.8% |
| ICU Medical | $175.10 | +0.01% | $4.38B | 148.4 | 19.7 | 2.0 | −0.2% |
| Median | 32.4 | 17.7 | 0.7 | +5.2% |